Company / EPS (Diluted)
Upstream Bio, Inc. EPS (Diluted) History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$5.58
FY2025
5-year range
-$12.95 / -$5.58
FY2023-FY2025
Trend
+56.9%
vs FY2024
Sector context
#181 of 204
Health Care
What the data says
Upstream Bio, Inc.'s eps (diluted) of $-5.58 is lower than 89% of companies in the Health Care sector (FY2025). Improved from $-12.95 to $-5.58 over the past 2 years.
Based on SEC 10-K filings.
-5.58 in FY2025.
Improved from $-12.95 to $-5.58 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 204This company -$5.58 Sector average -$0.89
▼
-529.6% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 56.9% year-over-year.
- Ranks #181 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.68 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$5.58 | +56.9% |
| FY2024 | -$12.95 | +0.0% |
| FY2023 | -$12.95 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026